Trial Profile

An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Regorafenib (Primary)
Indications Carcinoma; Leiomyosarcoma; Malignant melanoma; Malignant thymoma; Ovarian cancer; Pancreatic cancer; Sarcoma; Solid tumours; Synovial sarcoma; Thymoma
Focus Therapeutic Use
Acronyms RESOUND

Most Recent Events

09 Sep 2022 Status changed from active, no longer recruiting to completed.
27 Oct 2021 Primary endpoint has been met (activity of regorafenib screening, in terms of 2-months progression free survival rate) as per Results published in the Cancer
27 Oct 2021 Results published in the Cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com